Day Traders Tag icon

×
Monday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) compared to the investigator’s choice of chemotherapy. The study did not achieve statistical significance in the final overall survival (OS) analysis in patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative breast cancer previously treated with endocrine-based therapy and at least one systemic therapy. The study previously met the dual primary endpoint of progression-free survival. Also Read: AstraZeneca CEO Pascal Soriot Updates On Chinese Compliance Probe And Lung Cancer Drug Trial Results. An improvement in patient-reported outcomes was also seen. The safety profile of datopotamab deruxtecan was consistent with that observed in the ...


In The news